Piper Jaffray Companies reissued their overweight rating on shares of Vericel (NASDAQ:VCEL) in a research report report published on Tuesday morning, The Fly reports. Piper Jaffray Companies currently has a $9.00 target price on the biotechnology company’s stock.

Several other research firms also recently weighed in on VCEL. BTIG Research set a $6.00 price objective on Vericel and gave the company a buy rating in a report on Monday, October 2nd. ValuEngine downgraded Vericel from a hold rating to a sell rating in a report on Friday, December 1st.

Shares of Vericel (NASDAQ:VCEL) traded down $0.25 during mid-day trading on Tuesday, hitting $5.70. The company’s stock had a trading volume of 492,700 shares, compared to its average volume of 1,363,900. The company has a debt-to-equity ratio of 0.44, a quick ratio of 2.22 and a current ratio of 2.50. Vericel has a 52-week low of $2.25 and a 52-week high of $6.30. The firm has a market cap of $190.38, a P/E ratio of -6.48 and a beta of 3.02.

Vericel (NASDAQ:VCEL) last released its quarterly earnings data on Tuesday, November 7th. The biotechnology company reported ($0.16) earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.17) by $0.01. Vericel had a negative return on equity of 265.45% and a negative net margin of 45.11%. The company had revenue of $14.26 million for the quarter. analysts expect that Vericel will post -0.6 EPS for the current fiscal year.

Hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. First Washington CORP acquired a new stake in shares of Vericel during the 2nd quarter valued at $2,230,000. Perkins Capital Management Inc. boosted its holdings in shares of Vericel by 118.4% during the 3rd quarter. Perkins Capital Management Inc. now owns 562,600 shares of the biotechnology company’s stock valued at $3,376,000 after acquiring an additional 305,000 shares in the last quarter. Archon Capital Management LLC boosted its holdings in shares of Vericel by 95.7% during the 3rd quarter. Archon Capital Management LLC now owns 2,617,004 shares of the biotechnology company’s stock valued at $15,702,000 after acquiring an additional 1,279,925 shares in the last quarter. EAM Investors LLC acquired a new stake in shares of Vericel during the 3rd quarter valued at $943,000. Finally, Vanguard Group Inc. raised its position in Vericel by 7.9% during the 2nd quarter. Vanguard Group Inc. now owns 1,212,799 shares of the biotechnology company’s stock worth $4,002,000 after purchasing an additional 88,645 shares during the last quarter. 33.12% of the stock is currently owned by institutional investors.

ILLEGAL ACTIVITY WARNING: This story was first published by The Cerbat Gem and is owned by of The Cerbat Gem. If you are reading this story on another site, it was illegally copied and reposted in violation of U.S. & international copyright law. The correct version of this story can be read at https://www.thecerbatgem.com/2018/01/05/vericels-vcel-overweight-rating-reiterated-at-piper-jaffray-companies.html.

About Vericel

Vericel Corporation, formerly Aastrom Biosciences, Inc, is a commercial-stage biopharmaceutical company dedicated to the identification, development and commercialization of therapies that enable the body to repair and regenerate damaged tissues and organs to restore normal structure and function. The Company operates through the research, product development, manufacture and distribution of patient-specific, expanded cellular therapies for use in the treatment of specific diseases segment.

The Fly

Receive News & Stock Ratings for Vericel Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vericel and related stocks with our FREE daily email newsletter.